BioSpace News Archive

Following the death of a patient, Magenta Therapeutics placed a hold on Phase I/II dose-escalation trial of its acute myeloid leukemia therapy.

Ocuphire Pharma’s oral diabetic retinopathy drug missed the primary endpoint of an improvement in patient scores on the diabetic retinopathy severity scale.

Phase I/II data showed AC Immune’s anti-amyloid-beta vaccine candidate could safely elicit an antibody response in patients with Alzheimer’s disease. Now, it will expand to Down Syndrome patients.

A study published Tuesday in JAMA revealed VEXAS, a little-known syndrome with a high mortality rate, has a higher prevalence than previously thought.

Accuray Incorporated (NASDAQ: ARAY) announced today that the European Radiosurgery Center Munich has selected a second CyberKnife® System, the latest generation CyberKnife S7™ System, to enable their team to treat the high volume of patients they see in their practice who would benefit from the extremely precise radiation treatments it delivers.

Nautilus Biotechnology, Inc. today announced it will report financial results for the fourth quarter and full year of 2022 before market open on Thursday, February 23, 2023.

Soleno Therapeutics, Inc. today announced that results from the Company’s previously completed Phase 3 DESTINY PWS (C601) trial of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi Syndrome (PWS) have been published in a peer-reviewed journal.

PDS Biotechnology Corporation today announced its participation in the Channelchek Takeaway Series from the J.P. Morgan Healthcare Conference to be broadcast Thursday, January 26, starting at 10:00 a.m., EST.

ProSomnus, Inc. today announced that an abstract showcasing data from the First Line Obstructive Sleep Apnea Treatment study (FLOSAT) has been accepted for an oral presentation at the American Thoracic Society (ATS) 2023 International Conference, being held from May 19-24 in Washington, D.C.

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, is hosting an investor R&D Day today highlighting key aspects of Ventyx’s clinical-stage and discovery programs.